Review



isotype control igg  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Bio X Cell isotype control igg
    Isotype Control Igg, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 159 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/InVivoMAb+human+IgG1+isotype+control/pm42000926-68-10-15
    Average 96 stars, based on 159 article reviews
    isotype control igg - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Mouse Assay:

    Article Title: Targeting Endoglin Expressing Cells in the Tumor Microenvironment Does Not Inhibit Tumor Growth in a Pancreatic Cancer Mouse Model
    Article Snippet: .. Mice were randomized to treatment groups and treatment was given intraperitoneally (i.p.) twice a week with either 15 mg/kg bodyweight TRC105 (TRACON Pharmaceuticals, San Diego, USA) or human IgG control (BioXcell, West Lebanon, USA). .. For the combination therapy, mice were injected with anti-endoglin as described above and twice a week with either anti-PD-1 (clone J43, 10 mg/kg bodyweight, i.p. injection) or hamster IgG (both BioXcell, West Lebanon, USA).

    Article Title: Targeting Endoglin Expressing Cells in the Tumor Microenvironment Does Not Inhibit Tumor Growth in a Pancreatic Cancer Mouse Model
    Article Snippet: .. Mice were randomized to treatment groups and treatment was given intraperitoneally (i.p.) twice a week with either 15 mg/kg bodyweight TRC105 (TRACON Pharmaceuticals, San Diego, USA) or human IgG control (BioXcell, West Lebanon, USA). .. For the combination therapy, mice were injected with anti-endoglin as described above and twice a week with either anti-PD-1 (clone J43, 10 mg/kg bodyweight, i.p. injection) or hamster IgG (both BioXcell, West Lebanon, USA).

    Control:

    Article Title: Targeting Endoglin Expressing Cells in the Tumor Microenvironment Does Not Inhibit Tumor Growth in a Pancreatic Cancer Mouse Model
    Article Snippet: .. Mice were randomized to treatment groups and treatment was given intraperitoneally (i.p.) twice a week with either 15 mg/kg bodyweight TRC105 (TRACON Pharmaceuticals, San Diego, USA) or human IgG control (BioXcell, West Lebanon, USA). .. For the combination therapy, mice were injected with anti-endoglin as described above and twice a week with either anti-PD-1 (clone J43, 10 mg/kg bodyweight, i.p. injection) or hamster IgG (both BioXcell, West Lebanon, USA).

    Article Title: Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma.
    Article Snippet: All cell lines used were authentic and confirmed to be mycoplasma negative using the MycoAlert Mycoplasma Activity kit (Lonza). .. The following antibodies were used for treatment purpose: anti-human CD47 (BioXcell, Clone B6.H12), antimouse CD47 (BioXcell, clone MIAP301), human IgG control, and mouse IgG1 isotype control (BioXcell). .. To evaluate macrophage-mediated tumor phagocytosis42 in the presence of CD47 mAb, Saos-2 osteosarcoma cells were labeled with 1,1′-Dioctadecyl-3,3,3,’,3′tetramethylindodicarbocyanine (CellBriteTM Green, Biotium) according to the manufacturer’s protocol, and incubated at a 1:1 ratio with bone marrow-derived mouse macrophages in serum-free (Iscove's modified Dulbecco's medium (IMDM), with or without 10 μg/mL CD47 mAb at 37 °C for 4 h. To evaluate uptake of iron nanoparticles by macrophages in the presence of CD47 mAbs, we co-cultured murine bone marrow derived macrophages with unlabeled MNNG/HOS cells and FITC-labeled ferumoxytol (0.01 mM) with or without 10 μg/mL CD47 mAb at 37 °C for 4 h. Macrophages were then stained with F4/80 antibody and subsequently imaged using Leica SP8 confocal microscopy.

    Article Title: Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma.
    Article Snippet: .. Increased uptake of ferumoxytol nanoparticles generates T2 contrast on MR scans that can serve as an imaging biomarker for monitoring responses to CD47 immunotherapy Official journal of the Cell Death Differentiation Association human Cd11b (Biolegend, clone M1/70), APC anti-mouse F4/80 (eBioscience, clone BM8), Brilliant Violet 785TM antimouse I-A/I-E (MHC-II) (BioLegend, clone M5/114.15.2), Brilliant Violet 605TM anti-mouse CD86 (BioLegend, clone GL-1), PE anti-mouse CD206 (BioLegend, clone C068C2), PE/Cy7 anti-mouse CD124 (IL-4R alpha) (BioLegend, clone I015F8), Alexa Fluor® 488 anti-mouse CD80 (BioLegend, clone 16-10A1), CD163 (SantaCruz Biotechnology, M-96), CD68/SR-D1 (R&D Biosystems, clone #298807), anti-human CD47 (BioXcell, clone B6.H12), anti-mouse CD47 (BioXcell, clone MIAP301), CD47 (R&D Biosystems), human IgG control, mouse IgG1 isotype control (BioXcell), and anti-mouse CD16/CD32 (Mouse BD Fc BlockTM) (BD Biosciences, Clone 2.4G2). .. The following chemicals were used: Ferumoxytol (FerahemeTM, AMAG Pharmaceuticals), ProlongTM Gold antifade reagent with DAPI (Invitrogen), Zombie AquaTM Fixable Viability Kit (BioLegend), CellbriteTM red/green (Biotium), cisplatin (Sigma), and oxaliplatin (Sigma).

    Article Title: Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy
    Article Snippet: .. All mice were treated twice a week with intraperitoneal (IP) injections of 10mg/kg bodyweight M1043 or 15mg/kg bodyweight TRC105 (both kindly supplied by TRACON Pharmaceuticals, San Diego, CA, USA) or a human IgG control (inVivoMAB, BioXcell, West Lebanon, NH, USA). .. For the combination studies, mice were additionally treated twice a week with either an anti-PD1 (clone J43, 10mg/kg body weight, IP injection) or a hamster IgG control (both inVivoMAB, BioXcell, West Lebanon, NH, USA).

    Article Title: Targeting Endoglin Expressing Cells in the Tumor Microenvironment Does Not Inhibit Tumor Growth in a Pancreatic Cancer Mouse Model
    Article Snippet: .. Mice were randomized to treatment groups and treatment was given intraperitoneally (i.p.) twice a week with either 15 mg/kg bodyweight TRC105 (TRACON Pharmaceuticals, San Diego, USA) or human IgG control (BioXcell, West Lebanon, USA). .. For the combination therapy, mice were injected with anti-endoglin as described above and twice a week with either anti-PD-1 (clone J43, 10 mg/kg bodyweight, i.p. injection) or hamster IgG (both BioXcell, West Lebanon, USA).

    Article Title: Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma
    Article Snippet: All cell lines used were authentic and confirmed to be mycoplasma negative using the MycoAlert Mycoplasma Activity kit (Lonza). .. The following antibodies were used for treatment purpose: anti-human CD47 (BioXcell, Clone B6.H12), anti-mouse CD47 (BioXcell, clone MIAP301), human IgG control, and mouse IgG1 isotype control (BioXcell). .. To evaluate macrophage-mediated tumor phagocytosis in the presence of CD47 mAb, Saos-2 osteosarcoma cells were labeled with 1,1′-Dioctadecyl-3,3,3,’,3′-tetramethylindodicarbocyanine (CellBriteTM Green, Biotium) according to the manufacturer’s protocol, and incubated at a 1:1 ratio with bone marrow-derived mouse macrophages in serum-free (Iscove's modified Dulbecco's medium (IMDM), with or without 10 μg/mL CD47 mAb at 37 °C for 4 h. To evaluate uptake of iron nanoparticles by macrophages in the presence of CD47 mAbs, we co-cultured murine bone marrow derived macrophages with unlabeled MNNG/HOS cells and FITC-labeled ferumoxytol (0.01 mM) with or without 10 μg/mL CD47 mAb at 37 °C for 4 h. Macrophages were then stained with F4/80 antibody and subsequently imaged using Leica SP8 confocal microscopy.

    Imaging:

    Article Title: Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma.
    Article Snippet: .. Increased uptake of ferumoxytol nanoparticles generates T2 contrast on MR scans that can serve as an imaging biomarker for monitoring responses to CD47 immunotherapy Official journal of the Cell Death Differentiation Association human Cd11b (Biolegend, clone M1/70), APC anti-mouse F4/80 (eBioscience, clone BM8), Brilliant Violet 785TM antimouse I-A/I-E (MHC-II) (BioLegend, clone M5/114.15.2), Brilliant Violet 605TM anti-mouse CD86 (BioLegend, clone GL-1), PE anti-mouse CD206 (BioLegend, clone C068C2), PE/Cy7 anti-mouse CD124 (IL-4R alpha) (BioLegend, clone I015F8), Alexa Fluor® 488 anti-mouse CD80 (BioLegend, clone 16-10A1), CD163 (SantaCruz Biotechnology, M-96), CD68/SR-D1 (R&D Biosystems, clone #298807), anti-human CD47 (BioXcell, clone B6.H12), anti-mouse CD47 (BioXcell, clone MIAP301), CD47 (R&D Biosystems), human IgG control, mouse IgG1 isotype control (BioXcell), and anti-mouse CD16/CD32 (Mouse BD Fc BlockTM) (BD Biosciences, Clone 2.4G2). .. The following chemicals were used: Ferumoxytol (FerahemeTM, AMAG Pharmaceuticals), ProlongTM Gold antifade reagent with DAPI (Invitrogen), Zombie AquaTM Fixable Viability Kit (BioLegend), CellbriteTM red/green (Biotium), cisplatin (Sigma), and oxaliplatin (Sigma).

    Biomarker Discovery:

    Article Title: Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma.
    Article Snippet: .. Increased uptake of ferumoxytol nanoparticles generates T2 contrast on MR scans that can serve as an imaging biomarker for monitoring responses to CD47 immunotherapy Official journal of the Cell Death Differentiation Association human Cd11b (Biolegend, clone M1/70), APC anti-mouse F4/80 (eBioscience, clone BM8), Brilliant Violet 785TM antimouse I-A/I-E (MHC-II) (BioLegend, clone M5/114.15.2), Brilliant Violet 605TM anti-mouse CD86 (BioLegend, clone GL-1), PE anti-mouse CD206 (BioLegend, clone C068C2), PE/Cy7 anti-mouse CD124 (IL-4R alpha) (BioLegend, clone I015F8), Alexa Fluor® 488 anti-mouse CD80 (BioLegend, clone 16-10A1), CD163 (SantaCruz Biotechnology, M-96), CD68/SR-D1 (R&D Biosystems, clone #298807), anti-human CD47 (BioXcell, clone B6.H12), anti-mouse CD47 (BioXcell, clone MIAP301), CD47 (R&D Biosystems), human IgG control, mouse IgG1 isotype control (BioXcell), and anti-mouse CD16/CD32 (Mouse BD Fc BlockTM) (BD Biosciences, Clone 2.4G2). .. The following chemicals were used: Ferumoxytol (FerahemeTM, AMAG Pharmaceuticals), ProlongTM Gold antifade reagent with DAPI (Invitrogen), Zombie AquaTM Fixable Viability Kit (BioLegend), CellbriteTM red/green (Biotium), cisplatin (Sigma), and oxaliplatin (Sigma).

    Immunopeptidomics:

    Article Title: Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma.
    Article Snippet: .. Increased uptake of ferumoxytol nanoparticles generates T2 contrast on MR scans that can serve as an imaging biomarker for monitoring responses to CD47 immunotherapy Official journal of the Cell Death Differentiation Association human Cd11b (Biolegend, clone M1/70), APC anti-mouse F4/80 (eBioscience, clone BM8), Brilliant Violet 785TM antimouse I-A/I-E (MHC-II) (BioLegend, clone M5/114.15.2), Brilliant Violet 605TM anti-mouse CD86 (BioLegend, clone GL-1), PE anti-mouse CD206 (BioLegend, clone C068C2), PE/Cy7 anti-mouse CD124 (IL-4R alpha) (BioLegend, clone I015F8), Alexa Fluor® 488 anti-mouse CD80 (BioLegend, clone 16-10A1), CD163 (SantaCruz Biotechnology, M-96), CD68/SR-D1 (R&D Biosystems, clone #298807), anti-human CD47 (BioXcell, clone B6.H12), anti-mouse CD47 (BioXcell, clone MIAP301), CD47 (R&D Biosystems), human IgG control, mouse IgG1 isotype control (BioXcell), and anti-mouse CD16/CD32 (Mouse BD Fc BlockTM) (BD Biosciences, Clone 2.4G2). .. The following chemicals were used: Ferumoxytol (FerahemeTM, AMAG Pharmaceuticals), ProlongTM Gold antifade reagent with DAPI (Invitrogen), Zombie AquaTM Fixable Viability Kit (BioLegend), CellbriteTM red/green (Biotium), cisplatin (Sigma), and oxaliplatin (Sigma).



    Similar Products

    human igg kappa isotype control  (MedChemExpress)
    95
    MedChemExpress human igg kappa isotype control
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Human Igg Kappa Isotype Control, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Human+IgG1+kappa%2C+Isotype+Control/pmc13687270-36-7-15
    Average 95 stars, based on 1 article reviews
    human igg kappa isotype control - by Bioz Stars, 2026-11
    95/100 stars
    		  Buy from Supplier
    isotype control igg antibody  (TargetMol)
    94
    TargetMol isotype control igg antibody
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Isotype Control Igg Antibody, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Human+IgG1+lambda2%2C+Isotype+Control/pm42736388-85-13-20
    Average 94 stars, based on 1 article reviews
    isotype control igg antibody - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    human fab isotype control  (Novus Biologicals)
    94
    Novus Biologicals human fab isotype control
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Human Fab Isotype Control, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Human+IgG+F(ab)+Isotype+Control/pm42875473-626-0-7
    Average 94 stars, based on 1 article reviews
    human fab isotype control - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    anti human igg  (MedChemExpress)
    94
    MedChemExpress anti human igg
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Anti Human Igg, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Human+IgG1(D356E%2FL358M)+kappa%2C+Isotype+Control/bio_rxiv__64898__2026__10__01__756013-337-11-13
    Average 94 stars, based on 1 article reviews
    anti human igg - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    negative control  (Proteintech)
    96
    Proteintech negative control
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Negative Control, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Human+IgG+Antibody/pm42816419-294-46-49
    Average 96 stars, based on 1 article reviews
    negative control - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    control igg2b  (R&D Systems)
    91
    R&D Systems control igg2b
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Control Igg2b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Human+Dectin-2%2FCLEC6A+Antibody/pm42782101-272-9-18
    Average 91 stars, based on 1 article reviews
    control igg2b - by Bioz Stars, 2026-11
    91/100 stars
    		  Buy from Supplier
    isotype control igg  (Bio X Cell)
    96
    Bio X Cell isotype control igg
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Isotype Control Igg, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/InVivoMAb+human+IgG1+isotype+control/pm42000926-68-10-15
    Average 96 stars, based on 1 article reviews
    isotype control igg - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    isotype control human igg  (MedChemExpress)
    95
    MedChemExpress isotype control human igg
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Isotype Control Human Igg, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Human+IgG1+kappa%2C+Isotype+Control/pm42440198-84-28-33
    Average 95 stars, based on 1 article reviews
    isotype control human igg - by Bioz Stars, 2026-11
    95/100 stars
    		  Buy from Supplier
    human igg4 isotype control antibody  (InvivoGen)
    94
    InvivoGen human igg4 isotype control antibody
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Human Igg4 Isotype Control Antibody, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/Anti-%CE%B2-Gal-hIgG4/pm42430880-47-4-12
    Average 94 stars, based on 1 article reviews
    human igg4 isotype control antibody - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    rabbit anti human igg control  (Proteintech)
    96
    Proteintech rabbit anti human igg control
    The effect of <t>PTPN2/PTPN1</t> inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG <t>kappa</t> isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.
    Rabbit Anti Human Igg Control, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+igg+control/IgG+control+Antibody/pm41687608-280-214-218
    Average 96 stars, based on 1 article reviews
    rabbit anti human igg control - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    The effect of PTPN2/PTPN1 inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG kappa isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.

    Journal: Frontiers in Immunology

    Article Title: PTPN2/PTPN1 inhibition enhances ex vivo T- cell responses and potentiates mosunetuzumab activity in chronic lymphocytic leukemia

    doi: 10.3389/fimmu.2026.1948967

    Figure Lengend Snippet: The effect of PTPN2/PTPN1 inhibition on T cells activation and synapse formation. Peripheral blood CLL cells were treated with the indicated concentration of AC484 for 2 hours. DMSO treated cells served as controls (NT ). Following treatment, the cells were stimulated with Dynabeads ® Human T Cells-Activator CD3/CD28 for 24 hours at 37 °C. After incubation, the cells were stained with Pacific Blue Anti-Human CD8 or CD4 and PE Anti-Human CD69 or CD25. Samples were acquired by FACSCanto II (BD) and analyzed using BD FACSDiva software. (A) Quantification of %CD25+ cells in CD4 + population (n=10) (B) Quantification of %CD69+ cells in CD4 + population (n=10). (C) Quantification of %CD25+ cells in CD8 + population (n=10). (D) Quantification of %CD69+ cells in CD8 + population (n=10). (E–H) Subgroup analysis of CD25 or CD69 expression in CD8 + or CD4 + T cells population according to IGHV mutation status, (E, F) M-CLL (n=5) or (G, H) U-CLL (n=5), *p<0.05, **p<0.01, ***p<0.001. Data shown as mean+SD. (I–K) CLL cells were seeded on poly-L-lysine coated glass, then treated with 1µM AC484 for 2 hours. Then the cells were incubated with 1μg/mL of mosunetuzumab or human IgG kappa isotype control for 72 hours. The cells were fixed and permeabilized, followed by staining for CD8 (white), granzyme B (red), IgM (green) and DAPI (blue). Representative confocal images showing synapse formation between B cells (green) and CD8 + T cells (white). (I) Representative image of cells treated with the isotype control. (J) Representative image of cells treated with mosunetuzumab. (K) Representative image of cells treated with mosunetuzumab and the PTPN2/PTPN1 inhibitor AC484. Scale bar, 5 µm.

    Article Snippet: PTPN2/PTPN1 inhibitor ABBV-CLS-484 (AC484,Osunprotafib,HY-145923), mosunetuzumab (HY-P99033) and human IgG kappa isotype control (HY-P99001) were from MedChemExpress (USA).

    Techniques: Inhibition, Activation Assay, Concentration Assay, Incubation, Staining, Software, Analysis, Expressing, Mutagenesis, Glass, Control, Confocal